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Background: Dietary magnesium could modify the major stroke risk factors, high blood 1 
pressure (BP) and cholesterol, but has been understudied in both sexes in a single population. 2 
This study aimed to investigate if dietary magnesium intake was associated with BP, total 3 
cholesterol (TC) and incident stroke risk in an adult population. 4 
Methods: We conducted cross-sectional analyses in a case-cohort study of 4,443, men and 5 
women aged 40-75 representative of 25,639 participants years of the EPIC (European 6 
Prospective Investigation into Cancer)-Norfolk cohort. The cohort included 928 stroke cases 7 
(42,556.5 person years). Dietary data from 7d food diaries were analysed using multivariate 8 
regression to assess associations between quintiles or data-derived categories of dietary 9 
magnesium intake and BP, TC and stroke risk, adjusted for relevant confounders.  10 
Results: We observed differences of -7 mmHg systolic BP (P trend ≤0.01) and -3.8 mmHg 11 
diastolic BP (P trend 0.01) between extreme intakes of magnesium in men, a significant inverse 12 
association with TC was observed (P trend 0.02 men and 0.04 women). Compared to the 13 
bottom 10%, the top 30% of magnesium intake was associated with a 41% relative reduction 14 
in stroke risk (HR 0.59 95% CI 0.38-0.93) in men. 15 
Conclusions: Lower dietary magnesium intake was associated with higher BP and stroke 16 
risk, which may have implications for primary prevention.  17 
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1.0 INTRODUCTION  18 
Stroke accounts for more than 5.5 million deaths annually and by 2020 predictions estimate 19 
that the global burden of stroke will account for 61 million disability-adjusted life years (1). 20 
Elevated BP1 is a significant modifiable risk factor for stroke with an approximate fourfold 21 
increase in stroke risk in hypertensive individuals compared with the normotensive population 22 
(2).  Although established evidence indicates that elevated BP,  hypertension and circulating 23 
cholesterol can be modified by dietary intake including: salt, alcohol, saturated fat and 24 
cholesterol (2) other dietary components, including magnesium, which is abundantly available 25 
in nuts, green leafy vegetables and whole grains, have been less extensively studied.   26 
Magnesium has a number of metabolic roles in the body and may influence BP and blood lipids 27 
through different mechanisms (3, 4). Magnesium may serve as a natural calcium channel 28 
blocker, exhibit beneficial effects on platelet coagulation, have a potential role in vasodilation 29 
and has been associated with reduced coronary artery calcification (4, 5). Other proposed 30 
mechanisms include increased peroxidation of lipoproteins with subsequent acceleration of 31 
atherosclerotic plaque formation and low magnesium may facilitate an increase in 32 
inflammation which is associated with negative changes in lipid profile (3, 4). Higher 33 
magnesium intake has been associated with lower risk of Type II diabetes (6), metabolic 34 
syndrome (7) and cardiovascular disease (CVD) (8). 35 
Two recent meta-analyses have investigated the effects of dietary magnesium on stroke risk 36 
and CVD risk respectively (8, 9) showing inconsistent findings. The reason for these 37 
                                                 
1 Abbreviations 
7DD – seven day diet diary, BMI – body mass index, BP – blood pressure, CVD – cardiovascular disease, DBP 
– diastolic blood pressure, DINER - Data Into Nutrients for Epidemiological Research, EPIC-Norfolk – 
European Prospective Investigation into Cancer-Norfolk, FFQ – food frequency questionnaire, HDL – high 
density lipoprotein, HLQ – Health and Lifestyle Questionnaire, LDL – low density lipoprotein, MI – myocardial 
infarction, SBP – systolic blood press, TC – total cholesterol, WHR – waist-hip ratio 
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inconsistencies may be due to estimation of magnesium intakes from less precise methods of 38 
recording diet such as Food Frequency Questionnaires (FFQ) and 24 hour recalls. However, it 39 
has been increasingly suggested that the detailed 7DD represents dietary intakes more precisely 40 
(10).  41 
Therefore, the purpose of this study was to determine whether dietary magnesium intake, 42 
estimated using a 7DD, was associated with BP, lipid profile and stroke risk in an adult general 43 
population of 4,443 (representative of larger cohort 25,639) men and women. 44 
2.0 SUBJECTS AND METHODS  45 
2.1 Study population  46 
The present study population is comprised of a randomly selected representative sample 47 
(n=4,000) of the EPIC-Norfolk cohort (n~25,639), which will herein be referred to as EPIC-48 
Norfolk sub-cohort. EPIC-Norfolk has previously been described in detail and the 49 
characteristics of the sample was comparable with other representative UK populations with 50 
the exception of a lower proportion of current smokers (10). Ethical approval for the study was 51 
obtained from the Norwich Ethics Committee, and participants provided informed consent. 52 
Briefly this sub-cohort (n=4,920) is comprised of a representative random sample of 4,000 men 53 
and women with complete data for food diaries from the EPIC-Norfolk cohort (n=25,369) and 54 
1,102 stroke cases (n=182 part of 4,000 random sample previously mentioned) giving a total 55 
of 4,920. Participants were resident in the Norfolk area at recruitment between 1993 and 1997 56 
and recruited through participating General Practices (n=35) (10).  Participants were excluded 57 
from analyses if they had reported prevalent stroke at baseline or had missing values for any 58 
variables included in the multivariate model (n=477). Participants with missing values for 59 
smoking status, aspirin medication use for >3months, and magnesium from supplements 60 
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(including medication) were recoded and classified as ‘current smoking’ (n=37) and ‘no’ 61 
aspirin (n=813) and ‘no’ supplements (n=2) to reduce the risk of bias due to under-reporting. 62 
Therefore 4,443 participants remained for analysis in this study.  63 
2.2 Anthropometric Measures  64 
At baseline participants attended a health check, which took place either at a clinic or the 65 
participant’s GP surgery, where a number of anthropometric measurements were taken by 66 
trained staff according to standardised protocols (10). This included height to the nearest mm, 67 
using a free-standing stadiometer. Weight was recorded to the nearest 0.2kg with participants 68 
wearing light clothing and no shoes. From this measurement BMI was calculated. Waist and 69 
hip measurements were also recorded to the nearest mm (10).  70 
2.3 Clinical and Biological Measures  71 
BP was taken after participants had been seated for 3 mins. Two readings were taken using 72 
Accutorr Sphygmomanometer (Datascope, UK) with the participants arm in the horizontal 73 
position in line with the mid sternum (10). At the clinic visit, a non-fasting venous blood (42ml) 74 
sample was taken from which biochemical analysis for serum cholesterol was conducted (10). 75 
Stroke cases were defined as ICD-9 430-448 or ICD-10 60-69. Fatal and non-fatal stroke 76 
incidence was established using death certificate data and linkage with hospital records, using 77 
ICD-10 60-69 this method of stroke ascertainment has been shown to have high sensitivity and 78 
specificity (11). The current study is based on follow-up to 31st March 2008. Numbers of stroke 79 
are given in the tables.  80 
2.4 Lifestyle Factors  81 
Information was obtained from participants on a number of lifestyle variables via a Health and 82 
Lifestyle Questionnaire (HLQ). This included smoking status which was categorised as 83 
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current, if participants answered “yes” to the question “Do you smoke cigarettes now?”, never 84 
if they answered “no” to the question “Have you ever smoked as much as one cigarette a day 85 
for as long as a year”. All other participants with valid data were classified as former smokers 86 
(missing data were treated as ‘current’). Physical activity was assessed by the use of a short 87 
physical activity questionnaire which assessed typical activity over the previous 12 months. 88 
Physical activity status took account of both work and leisure related activities and participants 89 
were ranked into one of four categories (inactive, moderately inactive, moderately active and 90 
active) (10). The repeatability and validity of these was confirmed against heart-rate 91 
monitoring (12).   92 
Education level was determined from the HLQ and was defined at the highest qualification 93 
obtained at that time. Participants were ranked into one of four categories: ‘degree or 94 
equivalent’, A-level or equivalent’, ‘O-level or equivalent’, and less than O-level or 95 
equivalent’.  96 
2.5 Previous Medical History  97 
The presence of a number of existing underlying medical conditions was ascertained using the 98 
HLQ. Conditions of interest included; stroke, cancer, myocardial infarction and diabetes 99 
amongst others. In conjunction with this, participants were requested to detail any medication 100 
that they were currently taking.  101 
2.6 Dietary Assessment Method  102 
Participants were requested to record all food and drink items consumed within the 7 day period 103 
in a food record diary. Included in each food diary were colour photographs of 17 foods, each 104 
with three incremental portion sizes. Participants were requested to indicate which photograph 105 
best represented their portion size for each of the items. They were also asked to record the 106 
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weight of food items or use household measures to describe the portion size. The use of dietary 107 
supplements was also recorded within the diary, and data was input into a specifically designed 108 
program ViMiS (vitamin and mineral supplements) (13). The 7-day diary was chosen after 109 
validation studies showed its reproducibility and relative validity and indicated that the diet 110 
diaries provide a more accurate representation of dietary intakes, over FFQs (10, 14). These 111 
studies indicate that FFQs overestimate dietary intakes of a number of food groups including 112 
fruit and vegetables, milk and cheese which influence the magnesium intake estimates. 113 
A specific program, DINER (Data Into Nutrients for Epidemiological Research), was 114 
developed for entry of dietary information from the 7-day food diaries (15). DINER allows the 115 
detailed information provided in diet diaries to be translated into structured data files for 116 
nutritional analysis. The program is more flexible than other software which enables the detail 117 
of the diary, including cooking method, type of fat used and commercial brand names of 118 
products, to be retained (16). Due to the classification structure used to code food items DINER 119 
is also able to adapt to changes in food items available on the consumer market (15). The input 120 
of items from the food diaries requires a high level of detail, which reduces the risk of bias 121 
between coders, and analysis of consistency has echoed this (15).  Nutritionists, trained to use 122 
the DINERMO program, checked the entered data after which nutrient quantities were 123 
calculated and checked for a final time (17). 124 
The ratio of calcium to magnesium intake was calculated by dividing dietary calcium intake 125 
by dietary magnesium intake. 126 
2.7 Statistical Methods  127 
All statistical analyses were conducted using the statistical software Stata; version 11 128 
(StataCorp. College Station Tx, 2009). Continuous data are presented as mean with standard 129 
error and categorical data as number and percentage. A two-sided P-value of ≤0.05 was 130 
9 
 
considered statistically significant. Independent samples t test was used to asses differences in 131 
baseline characteristics between men and women. 132 
To account for sex differences associated with a number of variables of interest including BMI 133 
and WHR sex specific analyses were conducted. 134 
Multiple regression analysis with multivariate adjustment was employed to assess differences 135 
in SBP, DBP and total cholesterol TC with sex specific quintiles of dietary magnesium intake. 136 
Statistical Models 137 
Model 1 comprised of age, BMI, smoking, physical activity (PA) levels, education (all 138 
outcomes); use of antihypertensive medications (BP only); baseline reported myocardial 139 
infarction (MI) or diabetes, family history of stroke or MI, and use of statin medication (TC 140 
only) (2, 18, 19). Model 2, additionally adjusted for dietary factors, including total energy 141 
intake in order to demonstrate the effect of magnesium intake independent of total caloric 142 
intake, as well as previous incident myocardial infarction (MI) or diabetes at baseline, family 143 
history of stroke and MI (BP model only). Alcohol intake, dietary potassium and sodium were 144 
included due to their associations with BP (2) and total fat (TC model only). The use of calcium 145 
supplements and the ratio of calcium to magnesium intake were included; these two ions 146 
antagonise each other, may compete during intestinal absorption and the Ca:Mg ratio may be 147 
important for total mortality and coronary heart disease (20).  148 
For stroke risk, model 1 comprised age, BMI, smoking, PA, education and alcohol intake. 149 
Model 2 additionally adjusted for serum TC, baseline reported MI or diabetes and family 150 
history of stroke or MI. Model 3 included the addition of SBP and DBP, use of aspirin 151 
medication >3 months, use of antihypertensive medication, the ratio of dietary Ca:Mg and the 152 
use of calcium and magnesium supplements. 153 
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A modified Prentice-weighted Cox regression analysis, for case-cohort studies, was used to 154 
calculate hazard ratios with 95% CIs for the risk of incident of stroke in association with dietary 155 
magnesium intake (21). This modified method accounts for the potential overlap of participants 156 
with incident stroke and also randomly present in the representative sub-cohort. Analyses were 157 
conducted by sex-stratified data derived categories of magnesium intake with the lowest 10% 158 
of intakes (<214mg/d and <180mg/d for men and women), forming the reference category, and 159 
subsequent 30% groups of magnesium intake. This approach was taken as we hypothesised 160 
that the lowest risk of incident stroke would be in those with the highest dietary magnesium 161 
intakes. 162 
Sensitivity analysis was conducted excluding those taking antihypertensive and statin 163 
medication respectively. 164 
Total energy was not included as a covariate in cox regression analysis. This was for a number 165 
of reasons, including that in the cox regression we adjusted for classical risk factors for stroke 166 
and have previously adjusted for total energy in early BP analyses, which indicated that dietary 167 
magnesium intake has an effect on BP independently of total energy, specifically for men, and 168 
BP was included in cox regression analyses. Additionally with the inclusion of total energy 169 
there is potential for collinearity, as a number of covariates included in the model such as BMI, 170 
alcohol intake and physical activity are highly correlated with total energy intake. There is also 171 
the potential for over adjustment, and for these reasons we chose not to include total energy in 172 
the cox regression models.   173 
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3.0 RESULTS 174 
In the 4,443 participants included in these analyses 45.0% were male, with an age range of 39-175 
78 years. Mean BP was 140/85 (SD 18.5/11.5) and 136/82 (SD 19.5/11.4) mmHg for males 176 
and females respectively (Table 1). There was a total of 928 incident strokes during follow-up 177 
(mean 9.58 years; total person years 42,556.5) between 1993 and 2008. 178 
Men had significantly higher SBP, DBP and BMI and women had significantly higher TC 179 
levels (P for all <0.001), and BMI (P=0.01), but not family history of stroke or MI (P=0.35 and 180 
0.17 respectively), and antihypertensive or lipid lowering medication use (P=0.89 and 0.34 181 
respectively). This illustrates the need to conduct sex-stratified analyses. 182 
Both men and women with the lowest 10% of dietary magnesium intake, compared with the 183 
remaining 90% of intakes, tended to be older (64 vs. 61 years, and 63 vs. 60 years for men and 184 
women respectively), had a higher percentage of current smokers (18.6% vs. 10.9% and 21.1% 185 
vs. 12.0% for men and women respectively), inactive people (42.7% vs. 31.0% and 47.4% vs. 186 
31.2% for men and women respectively) and people taking antihypertensive medication 187 
(25.6% vs. 20.3% and 30.2% vs. 20.2% for men and women respectively). There was no 188 
substantial difference in BMI, use of statin or aspirin and MI or diabetes at baseline between 189 
lowest 10% of magnesium and remaining intakes. Across quintiles of dietary magnesium 190 
intake a significantly higher intake of fruit, vegetables and bread and cereals was seen in men 191 
and women (P<0.001 for all). 192 
 In men but not women, there were inverse associations between dietary magnesium intake and 193 
SBP and DBP that remained significant after analysis that accounted for age, dietary sodium 194 
intake and use of aspirin or antihypertensive medication (Table 2). There were differences of 195 
-7 mmHg and -3.8 mmHg between Quintile-1 and Quintile-5 in SBP and DBP (P≤0.01 and 196 
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P=0.01 respectively). In women there were no significant associations between dietary 197 
magnesium intake and SBP or DBP (Table 2). 198 
Significant inverse associations between dietary magnesium intakes and TC were identified for 199 
both genders (P=0.02 in men and P=0.04 in women) after adjustment for anthropometric and 200 
lifestyle factors (Table 2). However, these associations were attenuated with the addition of 201 
dietary factors; alcohol intake, total fat intake, ratio of Ca:Mg, total energy and calcium 202 
supplement intake to the multivariate model but remained significant (P=0.02 in men and 203 
P=0.04 in women) (Table 2).  204 
Sensitivity analysis excluding those on antihypertensive medication (n=1583 men and 1927 205 
women) or statin medication (n=1973 men and 2400 women) provided similar results. 206 
Stroke risk showed a non-significant inverse trend across quintiles of dietary magnesium 207 
intakes in men and women after adjustment (Table 3). In further analyses examining 208 
magnesium intake by categories there was a significant trend across categories in men. In those 209 
in the highest 30th percentile of dietary magnesium intake (Table 4), in men, but not in women 210 
(Table 4), there was a 41% relative reduction of stroke risk (HR 0.59 95% CI 0.38-0.93 211 
(P=0.04)) compared to the lowest 10% of magnesium intakes. Although stroke risk was also 212 
lower in women this was not significant. 213 
Sensitivity analyses excluding those taking antihypertensive medication attenuated the 214 
association of stroke risk in men to be non-significant and strengthened the association in 215 
women to be significant and separately excluding those taking statin medication attenuated the 216 
association in men to be non-significant.  217 
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4.0 DISCUSSION 218 
The main findings of this case-cohort study of British adults suggest that, after adjustment for 219 
several important confounding factors including age, smoking status, history of CVD, 220 
medication use, total energy intake and other dietary variables, there was a strongly significant 221 
association (P≤0.01) between dietary magnesium intake and SBP and DBP in men, but not in 222 
women. There was also an association with TC in both men and women (P=0.001 and P≤0.01 223 
respectively) which was attenuated but remained significant after adjustment for other dietary 224 
factors (P=0.02 and P=0.04 for men and women respectively). Furthermore in relation to stroke 225 
risk specifically, we identified a significant decrease in risk (HR 0.59 95% CI 0.38-0.93 226 
P=0.04) in men with dietary magnesium intakes ≥354 mg/d (the highest 30%) compared to 227 
those with intakes ≤214mg (the lowest 10%).  228 
Compared with our findings, previous studies have shown Previously a significant inverse 229 
association between dietary magnesium intake and SBP and DBP in men has also been reported 230 
(22) with differences of -6.4 mmHg and -3.1 mmHg for SBP and DBP respectively between 231 
those with the highest and lowest intakes in 615 older Japanese men (age 63-82 years) using 232 
24hr recall. Using 7d food diary data, a more robust measure of dietary intakes, in a 233 
representative general population of middle and older age we identified slightly greater 234 
differences in BP between extreme quintiles of magnesium intakes with a difference of -7 235 
mmHg (P<0.001) and -3.8 mmHg (P<0.001) for SBP and DBP respectively. We identified 236 
between quintiles differences were 250 mg/d for men, and 198mg/d for women, the equivalent 237 
to approximately 2 slices of wholemeal bread with peanut butter and 9 Brazil nuts, therefore 238 
achievable through dietary intakes (23). We also noted a tendency towards lower fruit, 239 
vegetable and bread and cereal intake in those with the lowest dietary magnesium intakes and 240 
may be relevant for identifying individuals whom may benefit from increased intake. 241 
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 In women a potential benefit from increased consumption of magnesium has previously been 242 
reported (24-26). Witteman et al (22) and Song et al (23) showed a reduction in relative risk 243 
RR 0.77 95%CI: 12%-33% and RR 0.93, 95% CI 0.86-1.02 respectively for developing 244 
hypertension in prospective studies using FFQs. Also a meta-analysis of RCTs using oral 245 
magnesium supplements also reported a dose dependent effect of supplementation on blood 246 
pressure (27). This is in contrast to the current study where we did not find any significant 247 
trends between magnesium intake and BP in women. This discrepancy may be due to 248 
differences in the models used. For example Witteman et al (1989) (24) did not adjust for 249 
lifestyle factors including physical activity levels and smoking status which are known to 250 
influence BP. We further explored why we might have identified differences between genders. 251 
It may be due to the fact that older age, higher BMI, and higher level of physical inactivity 252 
were more prevalent in women with low magnesium intakes which may in part explain why a 253 
significant effect was shown in men not women. As highlighted in the results section 254 
differences were identified between those with the lowest 10% of intakes and those with higher 255 
intakes, however, we took these factors into account during our analyses. It is also of note that 256 
differences identified were largely the same for both men and women, although there was a 257 
higher percentage of women, with the lowest 10% magnesium intakes, using antihypertensive 258 
medication which may influence the findings due to modifying effect of medication on future 259 
risk. In addition there was a narrower range of magnesium intakes for women (644mg/d) 260 
compared with men (744mg/d) which may attenuate the results. It may also be that the cohort 261 
was insufficiently powered to detect an affect in women. 262 
A number of intervention trials, using oral magnesium supplements, have reported significant 263 
reductions in BP ranging from 2.0 – 12.0 and 2.7 – 8.0 mmHg for SBP and DBP respectively 264 
(28-32). Although, the supplement doses were comparable with dietary intake, ranging 265 
between 200 mg/d to 600 mg/d, the formulations used were inconsistent.  266 
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Limited studies have previously investigated associations between dietary magnesium intake 267 
and TC or subfractions and two previous studies found no association with TC unlike our study 268 
which found that TC was ≈4% lower in Quintile-5 compared with Quntile-1 (33-36).  However, 269 
a higher magnesium intake has been related to beneficial increases in high density lipoprotein 270 
(HDL) concentrations (33, 35). 271 
Although several studies have previously investigated stroke risk and dietary magnesium 272 
intakes, to our knowledge none have included populations of both men and women 273 
simultaneously or included risk factors as well as stroke risk (26, 33-35, 37-42). Previous 274 
studies in large populations of American, Taiwanese and Northern European cohorts, which 275 
have mainly used food frequency questionnaires (FFQ), have reported no associations (26, 33, 276 
34, 38, 40-42). However, several studies found significant associations in men (35), women 277 
(43), and men and women (40). Additionally, a meta-analysis by Larsson et al (2012) (9), in 278 
241,378 people, reported an inverse association between dietary magnesium intake, recorded 279 
by FFQ, and risk of stroke. A more recent meta-analysis, of CVD, but not stroke specifically, 280 
by Del Gobbo et al (8) in 313,041 participants, concluded that there was no significant 281 
association between dietary magnesium intake and CVD. However, a significant inverse 282 
association was identified in relation to circulating magnesium and CVD incidence potentially 283 
indicating mechanisms that could also affect stroke risk. In addition Guasch-Ferré et al (44) 284 
recently reported that an increase in magnesium intake was associated with a decrease in both 285 
CVD mortality and total mortality in individuals at high CVD risk. Our results indicated a non-286 
significant trend across quintiles of dietary magnesium intake and stroke risk in men and 287 
women (Table 3). However, when we compared men with the lowest 10% of magnesium intake 288 
with the remainder of the cohort, we identified a significant inverse trend (P=0.04) across 289 
groups in men only (Table 4). This finding would suggest that it is the very lowest magnesium 290 
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intakes that may infer the greatest risk of stroke incidence, and the current findings suggest an 291 
association between lower dietary magnesium intake and higher stroke risk. 292 
4.1 Strengths and Limitations  293 
The strengths of the present analyses include; the size of the cohort, the representativeness of 294 
the UK general population and prospective design for the stroke analyses, which reduces the 295 
susceptibility of the study to selection bias. The study design also reduces the likelihood of 296 
measurement error, due to the recording of dietary intake at baseline prior to the onset of stroke. 297 
Additionally robust and systematic adjustment for a number of potential confounding factors 298 
allowed for the identification of dietary associations independent of known risk factors. It is 299 
possible that factors not included in the model may also influence associations such as 300 
medication use; proton pump inhibitors, and diuretics. The use of quantitative 7-day food 301 
diaries is likely to have provided a more accurate representation of micronutrient intakes, 302 
including magnesium intake, compared with FFQ and 24-hr recall methods (45). To our 303 
knowledge our study is the only one to use dietary intake values from 7-day diaries as opposed 304 
to estimates from FFQs. Seven day food diaries have been shown to more accurately represent 305 
dietary intakes of a number of food groups that contribute to magnesium intake, including fruit 306 
and vegetables, and micronutrient intakes including potassium, carotene and vitamin C in 307 
validation studies (14, 45, 46). Despite this, dietary intakes do not account for variation in 308 
bioavailability and absorption of magnesium, potentially the use of a biomarker would 309 
strengthen the findings (47) and we were also unable to take into account possible contributions 310 
of magnesium from drinking water (48). Furthermore in the same population we were able to 311 
examine the complex relationship between magnesium intake, BP and cholesterol and stroke 312 
risk taking into account potential relevant risk specific confounders.  313 
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Selection bias may be possible although the whole EPIC-Norfolk cohort was representative of 314 
the UK population, with comparable cohort characteristics, and the sub-cohort for these 315 
analyses was representative of the EPIC-Norfolk cohort. Furthermore, truncation of the sample 316 
distribution due to potential healthy responder bias would likely only attenuate the observed 317 
associations and therefore associations may actually be stronger than are presented. It should 318 
also be noted that, as with other cross-sectional and observational longitudinal studies, it is not 319 
possible to infer causation from these findings. However, the prospective relationship observed 320 
with dietary magnesium intake and stroke risk reduces the likelihood of reverse causality. 321 
Furthermore the associations were in agreement with the existing literature. Residual 322 
confounding is possible but, the likelihood is reduced due to previous validation of dietary 323 
methods and results of the EPIC-Norfolk cohort (46, 49). 324 
4.2 Summary  325 
To our knowledge this is the first study to investigate the association of dietary magnesium 326 
with BP, TC and stroke risk in a UK general population of both genders. The results suggest 327 
that increased dietary magnesium could positively impact on BP and stroke risk in men and 328 
total cholesterol levels in both genders. Our findings suggest that men with the lowest 329 
magnesium intakes are at the greatest risk of stroke, lower magnesium intake was also 330 
associated with higher blood pressure. Therefore a higher dietary magnesium intake may be 331 
beneficial for prevention of stroke in men and warrants further investigation.  332 
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Tables 
Table 1. Baseline characteristics by sex in 4443 men and women, aged 40-75 years in EPIC-
Norfolk cohort (1993-1997) 
 Men 
n=2000 
 
Women 
n=2443 
 
P-value1 
Age (years) 61.1 (±9.53) 60.4 (±9.71) 0.02 
BMI (kg/m2) 26.5 (±3.18) 26.2 (±4.24) <0.01 
Family History Stroke (%) 465 (23.3%) 601 (24.6%) 0.29 
Family History MI (%) 720 (36.0%) 934 (38.2%) 0.13 
Family History DM (%) 222 (11.1%) 305 (12.5%) 0.16 
Blood Pressure mmHg    
SBP 140 (±18.5) 136 (±19.5) <0.001 
DBP 85.3 (±11.5) 81.8 (±11.4) <0.001 
PP 54.2 (±11.2) 54.0 (±11.4) 0.66 
Antihypertensive Use (%) 417 (20.9%) 516 (21.1%) 0.83 
24 
 
Aspirin Use (%) 271 (13.6%) 197 (8.06%) <0.001 
Blood Lipids mmol/L    
Total Cholesterol 6.07 (±1.10) 6.36 (±1.22) <0.001 
Smoking (%)    
Current  234 (11.7%) 314 (12.9%) <0.001 
Former 1114 (55.7%) 774 (31.7%)  
Never 652 (32.6%) 1355 (55.5%)  
Physical Activity (%)    
Inactive 644 (32.2%) 800 (32.8%) <0.001 
Moderately Inactive 476 (23.8%) 790 (32.3%)  
Moderately Active 440 (22.0%) 514 (21.0%)  
Active 440 (22.0%) 339 (13.9%)   
Education Level (%)    
0 – No Qualifications 667 (33.4%) 1086 (44.5%) <0.001 
1 – O-Level or Equivalent 165 (8.3%) 249 (10.2%)  
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2 – A-Level or Equivalent 887 (44.4%) 822 (33.7%)  
3 – Degree or Equivalent 281 (14.1%) 286 (11.7%)  
Dietary Factors    
Total Energy (kcal/d) 2218 (±505) 1685 (±384) <0.001 
Magnesium (mg/d) 318 (±92.0)  265 (±73.2) <0.001 
Ca:Mg Ratio 2.93 2.93 0.96 
Potassium (mg/d) 3423 (±819)  2962 (±683) <0.001 
Alcohol (g/d) 15.9 (±20.8) 7.70 (±11.7) <0.001 
Sodium (mg/d) 3150 (±864) 2405 (±660) <0.001 
Calcium Supplement Use (%) 34 (1.70%) 160 (6.55%) <0.001 
Magnesium supplement use 
(%) 
22 (1.10%) 53 (2.17%) <0.01 
1P-value difference between males and females. 
Values are mean and standard deviations where continuous and number and percentage where 
categorical.  
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Table 2. Association of quintiles of dietary magnesium intake (range and mean quintile intake) and blood pressure and total cholesterol (means 
and SE) in 4443 men and women, aged 40-75 years in EPIC-Norfolk cohort (1993-1997). 
Men  Dietary Magnesium Intake  
  Q1 Q2 Q3 Q4 Q5  
  85-242 mg 
206 mg 
n=400 
243-284 mg 
266 mg 
n=400 
285-328 mg 
307 mg 
n=400 
329-385 mg 
355 mg 
n=400 
386-829 
456 mg 
n=400 
P for trend 
SBP Unadjusted 143 (±0.98) 140 (±0.97) 140 (±0.88) 139 (±0.90) 136 (±0.87) <0.001 
 Model 11 140 (±0.87) 139 (±0.86) 140 (±0.86) 140 (±0.86) 139 (±0.87) 0.64 
 Model 22 143 (±1.16) 140 (±0.90)* 3 140 (±0.85)*  138 (±0.89)**  136 (±1.18)***  0.002 
DBP Unadjusted 86.1 (±0.58) 85.9 (±0.60) 85.4 (±0.57) 85.2 (±0.56) 84.1 (±0.56) 0.008 
 Model 1 85.4 (±0.57) 85.4 (±0.56) 85.3 (±0.56) 85.5 (±0.56) 85.0 (±0.57) 0.68 
 Model 2 87.15 (±0.76) 86.1 (±0.59) 85.1 (±0.55)* 84.9 (±0.58)* 83.4 (±0.77)** 0.01 
27 
 
Women    
  48-204 mg 
176 mg 
n=489 
205-240 mg 
223 mg 
n=489 
241-274 mg 
258 mg 
n=489 
275-319 mg 
295 mg 
n=489 
320-692 mg 
374 mg 
n=488 
P for trend 
SBP Unadjusted 140 (±0.90) 135 (±0.85) 137 (±0.93) 135 (±0.89) 133 (±0.81) <0.001 
 Model 1 136 (±0.79) 135 (±0.77) 137 (±0.77) 136 (±0.77) 135 (±0.78) 0.85 
 Model 2 137 (±1.07) 135 (±0.82) 137 (±0.77) 135 (±0.81) 135 (±1.09) 0.45 
DBP Unadjusted 83.5 (±0.51) 81.5 (±0.50) 82.4 (±0.55) 80.9 (±0.53) 80.7 (±0.48) <0.001 
 Model 1 82.0 (±0.49) 81.3 (±0.48) 82.6 (±0.48) 81.4 (±0.48) 81.7 (±0.49) 0.71 
 Model 2 82.5 (±0.67) 81.6 (±0.51) 82.5 (±0.48)  81.1 (±0.51) 81.2 (±0.68) 0.26 
Men    
  Q1 Q2 Q3 Q4 Q5  
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  85-242 mg 
206 mg 
n=400 
243-284 mg 
266 mg 
n=400 
285-328 mg 
307 mg 
n=400 
329-385 mg 
355 mg 
n=400 
386-829 
456 mg 
n=400 
P for trend 
Total 
Cholesterol 
Unadjusted 6.21 (±0.06) 6.16 (±0.06) 6.02 (±0.05) 6.05 (±0.06) 5.91 (±0.05) <0.001 
 Model 14 6.17 (±0.06) 6.16 (±0.06) 6.03 (±0.05) 6.06 (±0.05) 5.93 (±0.06)** 0.001 
 Model 25 6.18 (±0.07) 6.16 (±0.06) 6.03 (±0.05) 6.06 (±0.06) 5.94 (±0.07)* 0.02 
Women    
  48-204 mg 
176 mg 
n=489 
205-240 mg 
223 mg 
n=489 
241-274 mg 
258 mg 
n=489 
275-319 mg 
295 mg 
n=489 
320-692 mg 
374 mg 
n=488 
P for trend 
Total 
Cholesterol 
Unadjusted 6.67 (±0.06) 6.35 (±0.05) 6.28 (±0.05) 6.32 (±0.05) 6.16 (±0.05) <0.001 
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 Model 13 6.51 (±0.05) 6.33 (±0.05)* 6.31 (±0.05)* 6.36 (±0.05)* 6.26 (±0.05)** 0.005 
 Model 24 6.52 (±0.06) 6.34 (±0.05)* 6.31 (±0.05)* 6.35 (±0.05) 6.25 (±0.06)* 0.04 
1Model 1: age, BMI, smoking status, physical activity, education level, antihypertensive medication use 
2Model 2: model 1 + baseline MI or diabetes, family history stroke, family history MI, alcohol intake, dietary sodium, potassium, ratio Ca:Mg, 
total energy and calcium supplement use (including contribution from medication) 
3Model 1: age, BMI, smoking status, physical activity, education level, baseline MI or diabetes, family history stroke, family history MI, statin 
medication use 
4Model 2: model 1 + alcohol, dietary total fat intake, ratio Ca:Mg, total energy and calcium supplement use (including contribution from 
medication). 
5P value for significance compared with Q1: *= P value ≤0.05, ** = P value ≤0.005, *** = P value ≤0.001 
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Table 3. Quintiles of dietary magnesium intake (range and mean quintile intake) at baseline (1993-1997) and stroke risk (HR and 95%CI), follow-
up March 2008, in 4443 men and women, aged 40-75 in EPIC-Norfolk cohort. 
Men       
 Q1 Q2 Q3 Q4 Q5  
 85-242 mg 
206 mg 
n=400 
243-284 mg 
266 mg 
n=400 
285-328 mg 
307 mg 
n=400 
329-385 mg 
355 mg 
n=400 
386-829 
456 mg 
n=400 
P trend 
Stroke Events 126 (30.6) 111 (26.9) 93 (22.6) 85 (20.6) 75 (18.3)  
Model 11 1.0 (reference) 0.85 (0.60-1.20) 0.70 (0.49-1.00) 0.86 (0.60-1.24) 0.80 (0.55-1.16) 0.22 
Model 22 1.0 (reference) 0.86 (0.60-1.20) 0.68 (0.47-0.99) 0.81 (0.56-1.17) 0.74 (0.50-1.09) 0.11 
Model 33 1.0 (reference) 0.87 (0.61-1.25) 0.73 (0.50-1.06) 0.80 (0.55-1.17) 0.81 (0.53-1.22) 0.21 
Women       
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 48-204 mg 
176 mg 
n=489 
205-240 mg 
223 mg 
n=489 
241-274 mg 
258 mg 
n=489 
275-319 mg 
295 mg 
n=489 
320-692 mg 
374 mg 
n=488 
 
Stroke Events 152 (30.5) 102 (20.5) 87 (17.5) 82 (16.5) 88 (17.7)  
Model 11 1.0 (reference) 0.74 (0.53-1.05) 0.74 (0.51-1.06) 0.84 (0.59-1.20) 0.83 (0.57-1.20) 0.39 
Model 22 1.0 (reference) 0.71 (0.50-1.01) 0.71 (0.49-1.03) 0.82 (0.57-1.17) 0.76 (0.52-1.11) 0.23 
Model 33 1.0 (reference) 0.72 (0.50-1.04) 0.73 (0.50-1.08) 0.86 (0.59-1.26) 0.82 (0.54-1.24) 0.45 
1model 1: age, BMI, education status, physical activity, smoking status, alcohol intake 
2model 2: model 1 + serum total cholesterol, baseline MI or diabetes, family history stroke, or MI  
3model 3: model 2 + SBP, DBP, aspirin use >3 months, antihypertensive medication, ratio Ca:Mg and magnesium and calcium supplement use 
(including contribution from medication)  
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Table 4. Stroke risk (HR 95% CI) by magnesium groups (range and mean intake), bottom 10% (Group 1 reference category) and 3 groups of 30% 
intakes each, in 4443 men and women, aged 40-75 in EPIC-Norfolk cohort. 
Men Group 1 
85-214 mg 
181 mg 
n=199 
Group 2 
215-285 mg 
254 mg 
n=605 
Group 3 
286-353 mg 
318 mg 
n=591 
Group 4 
354-828mg 
427 mg 
n=605 
P trend 
Stroke Events 65 (32.7%) 157 (26.0%) 123 (20.8%) 104 (17.2%)  
Model 11 1.00 0.73 (0.50-1.07) 0.63 (0.43-0.94)*4 0.67 (0.44-1.01) *4 0.07 
Model 22 1.00 0.72 (0.48-1.07) 0.61 (0.41-0.92) *4 0.61 (0.40-0.94) *4 0.03 
Model 33 1.00 0.67 (0.45-1.01)* 0.60 (0.40-0.90) *4 0.59 (0.38-0.93) *4 0.04 
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Women Group 1 
48-180 mg 
156 mg 
n=232 
Group 2 
181-240 mg 
213 mg 
n=745 
Group 3 
241-294 mg 
267 mg 
n=740 
Group 4 
295-691 mg 
352 mg 
n=726 
 
Stroke Events 73 (31.5%) 165 (22.2%) 126 (17.0%) 115 (15.8%)  
Model 11 1.00 0.73 (0.49-1.08) 0.70 (0.46-1.06) 0.74 (0.48-1.12) 0.27 
Model 22 1.00 0.67 (0.45-1.00) *4 0.65 (0.43-0.98) *4 0.66 (0.43-1.02) 0.14 
Model 33 1.00 0.65 (0.43-0.99) *4 0.65 (0.42-1.01) 0.69 (0.44-1.09) 0.27 
1model 1: age, BMI, education status, physical activity, smoking status, alcohol intake 
2model 2: model 1 + serum total cholesterol, baseline MI or diabetes, family history stroke, or MI 
3model 3: model 2 + SBP, DBP, aspirin use >3 months, antihypertensive medication, ratio Ca:Mg and magnesium and calcium supplement use 
(including contribution from medication)  
4P value for significance compared with reference (Group 1): *= P value ≤0.05 
